Research programme: amniotic stem cell therapies - Creative Medical Technology Holdings

Drug Profile

Research programme: amniotic stem cell therapies - Creative Medical Technology Holdings

Alternative Names: AmnioStem; AmnioStem universal donor stem cell; Amniotic fluid derived stem cell; Amniotic fluid stem cells

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Creative Medical Technology Holdings
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Primary ovarian insufficiency; Stroke

Most Recent Events

  • 04 Apr 2017 Creative Medical Technology files for patent protection for amniotic fluid derived stem cells therapy for radiation toxicity
  • 13 Dec 2016 Creative Medical Technology Holdings files for patent protection with the United States Patent and Trademark Office for amniotic stem cell therapies in USA
  • 02 Nov 2016 Creative Medical Technology Holdings in-licenses amniotic fluid stem cell patent from University of California System
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top